Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Amyotrophic Lateral Sclerosis (ALS) met Treeway
Volgen
we voegen er aldus een nieuw draadje bij voor deze nieuwkomer in de pijplijn van UniQure:www.cnbc.com/id/102336957 Treeway Announces License and Collaboration Agreement with uniQure to Develop a Gene Therapy for Amyotrophic Lateral Sclerosis (ALS) 4 Hours AgoPR Newswire COMMENTSStart the Discussion ROTTERDAM, the Netherlands, January 14, 2015 /PRNewswire/ -- Treeway B.V., founded by entrepreneurs Bernard Muller and Robbert Jan Stuit, both diagnosed with ALS, have announced a collaboration with uniQure N.V., a leading gene therapy company, (NASDAQ:QURE), to develop a gene therapy treatment for ALS. Under the terms of the licensing and collaboration agreement, uniQure has granted Treeway an exclusive license in this field to uniQure's relevant AAV5 viral vector and GDNF (Glial cell-derived neurotrophic factor) intellectual property. Treeway is responsible for the preclinical and clinical development of the ALS gene therapy treatment. uniQure will provide Treeway with its manufacturing capabilities and will further collaborate with Treeway on ALS gene therapy development. Treeway and uniQure will jointly commercialize any resulting ALS gene therapy with defined geographical rights for commercialization assigned to each company. Financial details of the agreement have not been disclosed. Inez de Greef, CEO of Treeway, is very pleased about this licensing, collaboration, and co-marketing agreement as it represents a major milestone in executing its mission to develop ALS therapy. "Gene therapy is an innovative and viable technology for developing an ALS therapy and has the potential to change the disease course of ALS. A collaboration between Treeway and uniQure will accelerate this development by bringing two unique companies together," says Ms. de Greef. Jörn Aldag, CEO of uniQure, adds: "We are impressed by the immense energy and will power of the Treeway founders in seeking a cure for ALS. We believe that by combining their disease know-how and uniQure's gene therapy platform and expertise, we can jointly achieve a step forward in the way ALS is treated in the future." Note for the editor about ALS Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's disease, is a relentless progressive neurodegenerative disease that causes muscle weakness, disability and eventually death, with a median survival of three years. To date, there is no cure for ALS. uniQure uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders. Our approach is validated by multiple partnerships and the regulatory approval of our lead product Glybera. www.uniQure.com Treeway B.V. Treeway is a biotechnology company and has been founded by entrepreneurs Bernard Muller and Robbert Jan Stuit, both diagnosed with ALS. Treeway's strategy is founded on a cohesive combination of approaches that together should provide the highest likelihood of bringing successful treatments for ALS to the patient in the short term. For questions and more information about Treeway, please contact via Inez de Greef info@treeway.nl or www.treeway.nl / +31-10-298-88-88. SOURCE Treeway B.V. zie ook:finance.yahoo.com/news/treeway-announ...
Wat is nieuw? Zie www.uniqure.com/partners/ Cedars-Sinai Regenerative Medicine Institute uniQure is part of a consortium led by the Cedars-Sinai Regenerative Medicine Institute that has initiated animal studies to find a basis for a gene therapy treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The Cedars-Sinai study involves scientists at the Regenerative Medicine Institute at Cedars-Sinai Medical Center; the University of Wisconsin, Madison; and uniQure. Cedars-Sinai recently received a $2.5 million grant from the US Department of Defense to underwrite the project. Click here for more information.
invoorentegenspoed schreef op 14 januari 2015 18:41 :
we voegen er aldus een nieuw draadje bij voor deze nieuwkomer in de pijplijn van UniQure [..]
Wellicht onder een nieuwe categorie "uniQure Collaboration Programs"... maar of het in de pipeline komt betwijfel ik nog een beetje. uniQure heeft namelijk zelf geen persbericht uitgestuurd. Wel jammer. En Treeway suggereert op haar website van een "eigen" pipeline.
ik denk ook niet dat dit de reden van de uptrend is. Op de conference had QURE wel leukere deals kunnen trachten te maken, contacten te leggen etc. De inkopers zijn al een poos bezig en hoewel deze gepubliceerde deal welkom is, niet baanbrekend genoeg om de uptrend mee te verklaren. Ik blijf van mening dat één (of meer) partijen bezig zijn om hun belang in QURE op te bouwen. De prijs tot boven de 23$ bleek geen enkele belemmering te zijn...dus much more to come (IMHO). Nu ook weer goed pump en dump zichtbaar: 300 stukjes waren voldoende om de koers ruim 70 cent lager te zetten! (van 22,80 naar 22,08)
Via Bernardus Muller twitter.com/bernardusmuller ALS patients press FDA for quick access to controversial biotech drugwww.washingtonpost.com/national/healt...
The BioReport Bernard Muller was a successful businessman in the maritime and oil industry, but when he was diagnosed with the neurodegenerative disease ALS in 2010, he turned his entrepreneurial skills toward developing new therapies to treat the disease. Muller co-founded the world’s largest genetic research project for ALS, project MinE, and launched Treeway, a biotech company developing new therapies for ALS. As the Biotechnology Industry Organization kicks off its BIO 2015 International Convention in Philadelphia June 15, Muller is a finalist as one of the organization’s Everyday Superheroes in the pharma/biotech category. We spoke to Muller about his decision to launch Treeway, the active role he sees for patients, and why he thinks traditional approaches to drug development and clinical trial design have not served ALS patients well.t.co/lQgOjL60wF
#BIO2015 Everyday Superhero Honorees Announced.Top Honoree: Bernard Muller, Founder & Chief Business Officer, Treeway. Pharma/Biotech Category The Pharma/ Biotech Category recognizes employees in the life science industry who have been instrumental in advancing therapies for patients. Top Honoree: Bernard Muller, Founder & Chief Business Officer, Treeway. Bernard calls himself Patient 3.0. He was diagnosed with ALS and took it as a challenge. In 2012, he co-founded the world’s largest genetic research project for ALS, project MinE. That same year, he also launched a biotech company with the aim of finding a cure or therapy for ALS. His company, Treeway, is now entering Phase 3 clinical trials with its lead product candidate.twitter.com/treewaytherapy/status/610...
CEDARS SINAI MEDICAL CENTER Clive Svendsen, Ph.D., Director & Professor, Board of Governors Regenerative Medicine Institute Oct. 8 | 4:30pm | La Jolla Ballroom 2 Los Angeles, CA (Non-Profit Hospital) Through funding from the California Institute for Regenerative Medicine (CIRM), Cedars Sinai Regenerative Medicine Institute is half-way through the preclinical and manufacturing process to take the world’s first combined stem cell and gene therapy product to treat ALS to the clinic. The product is a human neural progenitor line derived from fetal tissue expanded using a unique “chopping” method that avoids cell dissociation and maintains the cultures in an in vivo environment – closely adapted to that of the living host CNS. They are engineered to produce the powerful growth factor GDNF and then transplanted into the spinal cord of rodents and pigs to test for toxicity, tumorigenicity and migration. Following IND submission, the Institute will plan an 18 patient clinical trial at Cedars-Sinai using a new minimally invasive injection device with a unique unilateral design powered to show changes in progression in the treated limb. Cedars Sinai is partnering with uniQure for the next phase of commercialization of this product. www.cedars-sinai.edu tinyurl.com/ozga88d Conf.: 7/8/9 oct. In 2014... & 7/8/9 oct. 2015 Agenda 2015 komt in August..deze info is dus van 2014.
ALS dat eens zou werken,....:) :) :)
Waar staat het artikeltje met Jim Rogers?
The ALS Association Announces $11.6 Million in New Research Grants July 14, 2015 Today, The ALS Association announced its support of 58 new research grants totaling $11,621,638 to find treatments and a cure for the disease. These research awards include investigator-initiated grants, drug development contracts, Milton Safenowitz Postdoctoral Fellowships and support of the NEALS/TREAT ALS™ Clinical Trials Network. ...... Drug Development Contracts Drug development contracts are milestone-driven awards designed to rapidly bring the most promising potential therapies closer to clinical trials. Many of the contracts are in partnership with industry. Academic-industry partnerships are invaluable to drive treatment approaches for ALS more rapidly to the clinic. Clive Svendsen, Ph.D., Director of the Regenerative Medicine Institute at Cedars-Sinai Medical Center in Los Angeles, Calif. will receive $345,275 to develop AAV5-GDNF (TW002) for the treatment of ALS. This study is in partnership Treeway B.V. LTD, Rotterdam, The Netherlands.tinyurl.com/nspmhbj
Treeway announces collaboration with Cedars AAV5-GDNF (TW002) gene therapy for amyotrophic lateral sclerosis $QURE #ALS www.treeway.nl/treeway-announces-coll... Rotterdam, December 7th 2015 – Treeway is pleased to announce a collaboration with the Cedars-Sinai Board of Governors Regenerative Medicine Institute for the development of AAV5-GDNF (TW002) gene therapy for amyotrophic lateral sclerosis. Treeway, a biotech company founded by two ALS patients, obtained an exclusive license agreement from uniQure for the use of AAV5-GDNF earlier this year. GDNF has a promising clinical potential in ALS, but optimization of delivery to the site of action is required. AAV5-GDNF is a gene therapy with a novel administration modality for clinical use and is Treeway’s second product in development (TW002). To advance the development of AAV5-GDNF gene therapy, Treeway will work with a research team led by Clive Svendsen, PhD, director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute in Los Angeles. Svendsen is an expert in human neural stem cell biology and has specifically focused on using neural stem cells, modified to release GDNF, to treat ALS. Treeway and Cedars-Sinai applied for a TREAT ALS™Drug Development Contract and received the $500,000 award. The Drug Development Contract, an initiative of The ALS association, was designed to rapidly bring promising potential therapeutics closer to clinical trials. The TREAT ALS™Drug Development grant will be used to start a preclinical study in which the safety and efficacy of TW002 in an ALS rat model will be assessed further. The preclinical studies are an important step in the development of TW002 for ALS. Inez de Greef, CEO of Treeway, is pleased with the collaboration and says: “consistent with Treeway’s philosophy of ‘innovation by collaboration’ we believe that this research will help us to rapidly advance breakthrough science and further the goal of bringing new treatment approaches to ALS patients. We are grateful for the grant awarded by The ALS Association which enables us to jointly work on finding a cure for ALS.” “The ALS Association is pleased to support funding for academic-industry partnerships to expedite therapy development for ALS”, commented Lucie Bruijn, Ph.D. MBA Chief Scientist from the ALS association.
Art. Foliolum (dec.2016), P.6 mbt ALS Treeway incl.TW002issuu.com/psgroningen/docs/foliolum_d...
Even plakken.... Artificial microRNAs targeting C9ORF72 have the potential to reduce accumulation of the intra-nuclear transcripts in ALS (amyotrophic lateral sclerosis)and FTD (frontotemporal dementia) patients ac.els-cdn.com/S2162253119300149/1-s2... www.iex.nl/Forum/Topic/1306904/3/PubM... + What is Frontotemporal Dementia? Get the Essential Factstwitter.com/brightstarboise/status/10...
+ Targeting RNA-mediated toxicity in C9ORF72 ALS/FTD by RNAi-based gene therapy $QURE www.cell.com/molecular-therapy-family... $QURE Announces Publications on AAV Gene Therapy Approach to Treating Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) in the Journal Molecular Therapy Nucleic Acids tools.eurolandir.com/tools/Pressrelea...
Experimental Gene Therapy Successfully Silences Key #ALS Gene C9orf72, Preclinical Studies Show alsnewstoday.com/2019/02/18/gene-ther...
Don't forget this !alsnewstoday.com/2019/02/18/gene-ther... Experimental Gene Therapy Successfully Silences Key ALS Gene C9orf72, Preclinical Studies Show February 18, 2019 by Jose Marques Lopes, PHD A gene therapy candidate targeting a key amyotrophic lateral sclerosis (ALS) mutation in the C9orf72 gene is able to lower the accumulation of toxic RNA clumps and reduce the activity of this mutated gene, in cells collected from a patient with frontotemporal dementia (FTD) and in a mouse model of ALS, according to two preclinical studies. uniQure’s miQURE is designed to silence disease-causing genes while not causing off-target damage. It is intended to induce silencing of the entire target organ by using tiny, cell-derived vesicles called exosomes. The gene therapy candidates using miQURE incorporate micro-RNAs (miRNAs) — RNA molecules that regulate gene expression — that can be delivered with a type of harmless viral vector called an adeno-associated virus (AAV) to provide sustained activity. The most common genetic cause of familial and sporadic ALS and FTD — found in a substantial number of ALS patients and caused by progressive degeneration of the brain’s frontal and temporal lobes — is an expanded GGGGCC repeat, a sequence of four guanine (G) nucleotides followed by two cytosine (C) nucleotides in the first intron of C9orf72. While nucleotides are the building blocks of DNA, introns are DNA bits normally spliced out in protein production. In humans, loss-of-function mutations in C9orf72 — leading to reduced or complete lack of protein function — have not been associated with disease, suggesting that a reduction in this gene’s expression (protein production) is likely tolerable. Most studies linking C9orf72 to disease showed an accumulation of so-called RNA foci in the cell nucleus and deposition of specific proteins in the cytoplasm (within the cell but excluding the nucleus). RNA foci are toxic clumps of mutated C9orf72 RNA that sequester RNA-binding proteins, leading to cellular dysfunction and death. The two studies were conducted by scientists at uniQure and used the company’s miQURE technology, a next-generation gene-silencing platform. Both were published in the journal Molecular Therapy – Nucleic Acids. In the first, “Artificial microRNAs targeting C9orf72 can reduce accumulation of the intra-nuclear transcripts in ALS and FTD patients,” the researchers showed that miQURE’s miRNAs lead to lower levels of the C9orf72 messenger RNA — generated from DNA to produce the protein — in both the cell nucleus and the cytoplasm. Findings also revealed an approximately 50% reduction in RNA foci in cells expressing the mutant form of C9orf72. Then, two different miRNA candidates — miC-101 and miC-451 — were incorporated into the AAV5 subtype of the viral vector. This enabled silencing of C9orf72 in vitro, including in neurons derived from induced pluripotent stem cells (iPSCs) from a patient with FTD. iPSCs are developed by reprogramming cells so that they revert to an embryonic-like state to grow into all cell types. The second study, “Targeting RNA-mediated toxicity in C9orf72 ALS/FTD by RNAi based gene therapy,” further showed that AAV5 carrying miRNAs that target C9orf72 are able to reduce the accumulation of C9orf72 RNA, as well as induce silencing of the target gene in both the nucleus and cytoplasm. The previously shown reductions in C9orf72 RNA and RNA foci were then validated in a mouse model of ALS that carries the human form of the mutant gene. Reduction in C9orf72 RNA were found in the brain’s striatum, a key brain area in motor control, upon delivery of the potential gene therapy specifically into this region. “Our data provide evidence on the efficacy of artificial miRNAs against C9orf72 as a promising AAV-based gene therapy for ALS and FTD,” the scientists wrote. Sander van Deventer, MD, PhD, uniQure’s chief scientific officer, said in a press release that the ability to silence C9orf72 in the nucleus “may prove to be critical for therapeutic efficacy of gene therapies for these diseases.” These results support the continuation of uniQure’s gene therapy program in ALS and FTD, according to van Deventer, who also said, “We are very pleased to have these data published in a highly relevant journal for the field and look forward to further exploring this opportunity.”
Zeker niet vergeten, maar wel kritisch blijven. Prof. dr. Jeroen Pasterkamp: "We hebben wel gevonden dat het uitschakelen van het C9orf72-eiwit tot ziekte van het immuunsysteem en kanker kan leiden. Dit betekent dat we dus voorzichtig moeten zijn met het uitschakelen van het mutante eiwit als therapie voor ALS-patiënten." www.als-centrum.nl/kennisplatform/rol...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
866,51
0,00%
EUR/USD
1,0647
-0,05%
FTSE 100
8.023,87
0,00%
Germany40^
17.981,70
+0,68%
Gold spot
2.301,06
-1,13%
NY-Nasdaq Composite
15.451,31
+1,11%
Stijgers
Dalers